Patient Square Capital

LXE Hearing is a company focused on championing hearing wellness for everyone, everywhere. The company's mission is to revolutionize hearing wellness through innovation, ensuring access to affordable, life-enhancing solutions.

Patterson Companies, Inc. is a leading distributor of dental and animal health products, operating primarily in the United States, with additional markets in the United Kingdom and Canada. The company is structured into three segments: Dental, Animal Health, and Corporate. The Dental segment supplies a wide range of consumable products, dental equipment, and technology solutions, alongside various services such as maintenance and financing. The Animal Health segment focuses on distributing pharmaceuticals, vaccines, diagnostics, and nutritional products, while also offering private label items under established brands. The Corporate segment provides customer financing services and miscellaneous products. Patterson Companies serves a diverse clientele that includes dentists, laboratories, veterinarians, and other healthcare professionals. Founded in 1877 and headquartered in Saint Paul, Minnesota, the company was originally known as Patterson Dental Company before rebranding in 2004.

CorroHealth is a specialized provider of analytics-driven solutions for healthcare systems, focusing on enhancing revenue cycle management. They employ advanced analytics and proprietary AI technologies to optimize financial performance in hospitals and other healthcare facilities by navigating regulatory complexities, streamlining integration processes, reducing physician burdens, and improving overall financial outcomes.

Nuclera specializes in accelerating drug discovery by providing a protein prototyping system. Its eProtein Discovery™ platform enables scientists to rapidly produce and test proteins for research purposes.

GondolaBio is a biopharmaceutical company dedicated to researching, developing, and manufacturing pharmaceutical products. Its primary focus is on creating therapeutics for patients with genetic diseases, addressing high unmet medical needs across various therapeutic areas and stages of development. The company leverages biological research to drive its mission, aiming to enable the healthcare industry to effectively treat and manage rare genetic conditions.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Apollo Therapeutics is a collaborative biopharmaceutical venture bridging three UK universities—Imperial College London, University College London, and the University of Cambridge—and three global pharmaceutical companies—AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. It provides translational funding and drug discovery expertise to translate fundamental academic research into medicines, supporting preclinical and clinical development. The company builds an expansive, de-risked portfolio across oncology, major inflammatory disorders, and rare diseases, focusing on assets with strong biological hypotheses. Its team of industry scientists works with academics and industry partners to tailor projects, aiming to accelerate the path from discovery to the clinic and improve patient outcomes. By leveraging the UK science base and domestic pharma capabilities, Apollo Therapeutics seeks to deliver new therapies that address significant medical needs.

Syneos Health is a global biopharmaceutical solutions organization, offering a comprehensive range of services from clinical research to commercialization. Established in 1985 and headquartered in Raleigh, North Carolina, the company supports clients across six continents. Syneos Health provides phase I to IV clinical development services, connecting customers, research sites, and patients to expedite new medicine delivery. Its services span biometrics, data operations, regulatory consulting, and commercial solutions, including sales and marketing support. With approximately 24,000 employees, Syneos Health is uniquely positioned to accelerate customer performance in the modern biopharmaceutical market.

Apollo Therapeutics is a collaborative biopharmaceutical venture bridging three UK universities—Imperial College London, University College London, and the University of Cambridge—and three global pharmaceutical companies—AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. It provides translational funding and drug discovery expertise to translate fundamental academic research into medicines, supporting preclinical and clinical development. The company builds an expansive, de-risked portfolio across oncology, major inflammatory disorders, and rare diseases, focusing on assets with strong biological hypotheses. Its team of industry scientists works with academics and industry partners to tailor projects, aiming to accelerate the path from discovery to the clinic and improve patient outcomes. By leveraging the UK science base and domestic pharma capabilities, Apollo Therapeutics seeks to deliver new therapies that address significant medical needs.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Elevage Medical Technologies supports medical device companies developing innovative technologies to enhance patient health outcomes and improve quality of life.

Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.

Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.

Hanger, Inc. is a leading health care company based in Austin, specializing in orthotic and prosthetic (O&P) services and products. It operates primarily through two segments: Patient Care and Products and Services. The Patient Care segment, which is the main revenue driver, includes Hanger Clinic, which focuses on the design, fabrication, and delivery of custom O&P devices across more than 700 clinics. Additionally, the Products and Services segment provides distribution and therapeutic solutions to various businesses. Hanger, Inc. is recognized for its commitment to clinical excellence and patient-centered care, leveraging advanced technologies to enhance or restore the physical capabilities of individuals with disabilities or injuries.

Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics for food allergy. Based in Menlo Park, California, it was founded in 2018. The company’s lead program, ADP101, is a broad-spectrum oral immunotherapy designed to mitigate, treat, and prevent reactions to foods by targeting single or multiple allergen proteins across common allergens.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Enavate Sciences is a growth-focused investment firm based in New York that backs life sciences companies developing therapeutic products and enabling technologies. The firm targets therapeutic and technology companies across preclinical and clinical stages, providing capital and strategic support to accelerate product development, validation, and market expansion.

Access TeleCare is a provider of acute care telemedicine services designed for hospitals, health systems, post-acute providers, and physician networks. The company specializes in a range of telehealth services, including telecardiology, teleneurology, telepsychiatry, telepulmonology, telehospitalists, teleinfectious disease, and telematernal fetal medicine. By leveraging advanced technology, Access TeleCare facilitates virtual patient care, allowing healthcare organizations to develop and sustain telemedicine programs across various clinical specialties. The company's model supports healthcare providers in enhancing patient access to specialized care while maintaining quality and efficiency in service delivery.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

Summit Behavioral Healthcare, LLC operates a network of behavioral health centers focused on addiction treatment and related services. Founded in 2013 and based in Brentwood, Tennessee, the company has expanded its reach to multiple states, including California, Missouri, Georgia, Pennsylvania, Louisiana, South Carolina, and Texas. Summit BHC provides a comprehensive range of programs, such as residential chemical dependency treatment, detoxification, partial hospitalization, and intensive outpatient services. The organization is dedicated to supporting adults and families dealing with addiction to alcohol and other drugs, addressing the underlying stressors contributing to substance use. By offering evidence-based treatment options in a supportive environment, Summit aims to facilitate recovery and promote long-term well-being for its patients.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Apollo Therapeutics is a collaborative biopharmaceutical venture bridging three UK universities—Imperial College London, University College London, and the University of Cambridge—and three global pharmaceutical companies—AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. It provides translational funding and drug discovery expertise to translate fundamental academic research into medicines, supporting preclinical and clinical development. The company builds an expansive, de-risked portfolio across oncology, major inflammatory disorders, and rare diseases, focusing on assets with strong biological hypotheses. Its team of industry scientists works with academics and industry partners to tailor projects, aiming to accelerate the path from discovery to the clinic and improve patient outcomes. By leveraging the UK science base and domestic pharma capabilities, Apollo Therapeutics seeks to deliver new therapies that address significant medical needs.